ISSN 2348-1218 (print)
International Journal of Interdisciplinary Research and Innovations ISSN 2348-1226 (online)
Vol. 14, Issue 3, pp: (106-127), Month: July 2026 - September 2026, Available at: www.researchpublish.com

And the Leaves of the Trees are for the Healing of the Nations (Revelation 22:2): Medicinal Herbs, Pharmaceutical Power, and the Future of Integrative Healthcare

David Bull

Ed.D., PhD, DBA, MBA, MSc, BCMHC, PMP.

American InterContinental University System.

DOI: https://doi.org/10.5281/zenodo.22828122

Published Date: 18-September-2026

Abstract: **Medicinal plants have long contributed to traditional healing and pharmaceutical discovery, yet their relationship with pharmaceutical science, commercial interests, regulation, and contemporary healthcare remains contested. Drawing on Revelation 22:2 "the leaves of the tree are for the healing of the nations"—this study examines medicinal plants without presupposing an exclusively physical, medicinal, spiritual, symbolic, or eschatological interpretation of the text. An integrative literature review and conceptual analysis synthesized 62 sources spanning biblical scholarship, traditional and Indigenous medicine, ethnopharmacology, natural-product drug discovery, pharmaceutical studies, public health, regulation, and integrative healthcare. Findings indicate that traditional medicinal knowledge and pharmaceutical science are neither inherently incompatible nor interchangeable. Traditional knowledge can contribute to therapeutic discovery, while scientific evaluation, standardization, quality assurance, safety assessment, and appropriate clinical evidence remain essential for responsible healthcare application. The findings further demonstrate that pharmaceutical influence, commercialization, intellectual property, regulatory authority, and institutional power shape the recognition, development, ownership, and accessibility of medicinal-plant therapies, raising concerns regarding community rights, biodiversity, and equitable benefit sharing. Overall, the study supports an evidence-informed approach to integrative healthcare that moves beyond the herbal–pharmaceutical dichotomy by bringing traditional knowledge, scientific validation, pharmaceutical innovation, patient safety, cultural respect, ethical governance, and equitable participation into constructive relationship.**

Keywords: **medicinal plants, herbal medicine, traditional medicine, pharmaceutical influence, pharmaceutical power, integrative healthcare, traditional knowledge, Revelation 22:2.**

I. INTRODUCTION

Across civilizations, plants have occupied an important place at the intersection of medicine, culture, spirituality, and human survival. Long before modern pharmaceutical science, communities identified, prepared, and used plants to prevent illness, relieve suffering, and restore health. African traditional medicine, Traditional Chinese Medicine, Ayurveda, and numerous Indigenous healing systems developed substantial bodies of medicinal knowledge through observation, experience, and intergenerational transmission (Alum, 2024). Although these traditions differ in philosophy and practice, they demonstrate the enduring role of medicinal plants in humanity's response to disease.

Within the Judeo-Christian tradition, the relationship between the natural world and healing finds a striking expression in Revelation 22:2. In John's vision, the tree of life stands beside the river of the water of life, "bearing twelve crops of fruit, yielding its fruit every month. And the leaves of the tree are for the healing of the nations" (New International Version, 2011, Revelation 22:2). This imagery recalls Ezekiel 47:12, where trees beside life-giving waters bear fruit for food and leaves "for healing." Revelation extends this association by explicitly identifying "the nations" as recipients of healing (Mathewson, 2021).

The nature of the healing described in Revelation 22:2 has been interpreted in different ways. Rather than restricting the passage in advance to either a spiritual-symbolic or physical-medicinal meaning, this paper allows its explicit association among leaves, healing, and the nations to stand while examining it alongside humanity's historical and contemporary experience with medicinal plants. Contemporary biblical scholarship continues to examine the significance of the healing leaves in relation to restoration, the nations, and the tree of life (Meverden, 2026). Revelation 22:2 therefore serves as a biblical point of departure for examining relationships among plants, healing, restoration, and human well-being without predetermining the full theological or medicinal significance of the text.

This inquiry remains relevant because plant-based healing is neither confined to antiquity nor disconnected from modern medicine. Traditional and Indigenous knowledge has contributed to the identification of medicinal resources worthy of scientific investigation, while natural products and their derivatives continue to contribute to pharmaceutical discovery (Alum, 2024; Atanasov et al., 2021; Zhang et al., 2024). The boundary between herbal and pharmaceutical medicine is consequently more permeable than a simple distinction between “natural” and “modern” medicine suggests. A medicinal plant may move from traditional observation through scientific characterization, safety and efficacy evaluation, standardization, and regulation into contemporary therapeutic use.

This relationship, however, raises questions extending beyond pharmacology. Traditional medicinal knowledge has often resided within families, communities, traditional healers, and Indigenous knowledge systems. When such knowledge contributes to commercially valuable therapeutic products, issues of recognition, intellectual property, ownership, bioprospecting, biopiracy, and equitable benefit sharing emerge (Alum, 2024). Medicinal plants may therefore function simultaneously as therapeutic resources, cultural heritage, sources of scientific discovery, and commercial commodities.

These concerns intersect with phamaceutical influence and pharmaceutical power. Pharmaceutical science has contributed profoundly to disease prevention, treatment, symptom control, and increased life expectancy. Pharmaceutical power, as used in this paper, does not presume that pharmaceutical development is inherently harmful or opposed to traditional medicine. Rather, it draws attention to how research funding, commercial incentives, intellectual-property systems, regulatory structures, scientific institutions, and markets influence which therapeutic resources are investigated, validated, commercialized, and incorporated into healthcare. The controversy is therefore not adequately captured as a contest between herbs and pharmaceuticals; it also concerns whose knowledge is recognized, what counts as acceptable evidence, who controls therapeutic development, and who benefits from commercialization.

At the same time, recognition of traditional medicinal knowledge cannot eliminate legitimate questions concerning safety, efficacy, quality, and appropriate clinical use. Medicinal plants contain biologically active substances that may produce therapeutic effects but may also cause toxicity, adverse reactions, contraindications, and herb–drug interactions. Variability in species, preparation, concentration, contamination, adulteration, labeling, and dosage further complicates clinical use (Jütte et al., 2024). Scientific investigation and traditional knowledge therefore need not be treated as mutually exclusive: rigorous evaluation can protect patients while also providing a means of investigating therapeutic observations originating within traditional knowledge systems.

International health policy increasingly reflects this more integrative direction. The World Health Organization's *Global Traditional Medicine Strategy 2025–2034* emphasizes stronger evidence, safety, appropriate regulation, health-system integration, Indigenous rights, biodiversity, equity, and responsible stewardship (World Health Organization [WHO], 2025). Regulatory experience likewise demonstrates that botanical and pharmaceutical medicines are not necessarily mutually exclusive categories; plant-derived products can enter formal therapeutic-development pathways when supported by appropriate standards of quality, safety, and effectiveness.

The emerging challenge is therefore not simply whether healthcare should favor herbs or pharmaceuticals. It is how potentially valuable traditional medicinal knowledge, scientific investigation, pharmaceutical innovation, patient safety, cultural recognition, ethical commercialization, and equitable access can be brought into a responsible relationship. Evidence-informed integrative healthcare provides one setting in which these relationships can be examined without assuming that all traditional therapies should be accepted, pharmaceuticalized, or incorporated into clinical practice.

Problem Statement

Despite the longstanding use of medicinal plants and the continuing contribution of natural products to therapeutic discovery, traditional herbal medicine and pharmaceutical medicine are frequently positioned as competing rather than interconnected domains of healing. This division can obscure the contribution of traditional knowledge to medicinal

discovery while legitimate concerns persist regarding evidence, safety, standardization, quality, and regulation. Phamaceutical influence, intellectual-property arrangements, commercial interests, and institutional authority further raise questions about whose knowledge receives scientific recognition, which therapeutic resources attract research investment, how medicinal knowledge becomes commercial property, and whether communities that preserve such knowledge participate equitably in resulting benefits. Contemporary healthcare therefore faces the challenge of investigating potentially valuable traditional medicinal knowledge while maintaining appropriate scientific and safety standards and addressing the cultural, ethical, economic, and regulatory dimensions of therapeutic development.

Even though extensive research have been conducted on medicinal plants, traditional medicine, natural-product drug discovery, pharmaceutical development, and integrative healthcare, these bodies of knowledge remain substantially fragmented. Limited interdisciplinary scholarship has examined how biblical and historical understandings of plant-based healing intersect with traditional and Indigenous medicinal knowledge, scientific validation, pharmaceutical development, commercial and institutional power, intellectual-property systems, and contemporary efforts to integrate herbal medicine responsibly into healthcare. Consequently, insufficient attention has been given to the full pathway through which plant-based therapeutic knowledge is recognized, investigated, validated, standardized, commercialized, regulated, owned, and made accessible, and to how these processes affect the communities from which medicinal knowledge and biological resources may originate. Addressing this gap requires an integrative analysis that moves beyond the conventional herbal–pharmaceutical dichotomy to examine evidence, safety, power, ownership, equity, and responsible healthcare integration within a common analytical perspective.

Purpose of the Paper

The purpose of this integrative literature review and conceptual analysis is to critically examine the relationships among medicinal herbs, traditional healing knowledge, pharmaceutical power, and evidence-informed integrative healthcare, using Revelation 22:2 as a biblical point of departure. Specifically, the paper examines the historical and cross-cultural foundations of medicinal-plant use; the contribution of traditional knowledge to pharmaceutical discovery; the scientific, safety, and regulatory issues associated with herbal medicine; and the influence of phamaceutical influence, commercialization, intellectual property, and institutional authority on the recognition and development of plant-based therapies. It further considers how traditional knowledge, scientific validation, pharmaceutical innovation, ethical governance, equitable benefit sharing, and patient-centered care can contribute to evidence-informed integrative healthcare.

Research Questions

The paper is guided by the following research questions:

RQ1. How have biblical, historical, traditional, and cross-cultural understandings of medicinal plants contributed to concepts and practices of healing?

RQ2. How has traditional medicinal knowledge contributed to the discovery, scientific investigation, and pharmaceutical development of plant-derived therapies?

RQ3. How do phamaceutical influence, commercial interests, intellectual-property systems, regulatory structures, and institutional authority influence the recognition, development, ownership, and accessibility of medicinal-plant therapies?

RQ4. What scientific, safety, ethical, cultural, and regulatory challenges affect the incorporation of herbal medicine into contemporary healthcare?

RQ5. How can traditional medicinal knowledge, scientific validation, pharmaceutical innovation, ethical governance, and equitable benefit sharing contribute to evidence-informed integrative healthcare?

Conceptual and Theoretical Foundations

The relationship among medicinal plants, traditional healing, pharmaceutical development, and integrative healthcare spans multiple disciplinary and knowledge traditions. Accordingly, this review is guided by four complementary analytical perspectives: biblical healing and restoration, traditional and Indigenous knowledge systems, phamaceutical influence and the political economy of medicine, and integrative healthcare. These perspectives function as sensitizing lenses for examining how medicinal knowledge is generated, recognized, investigated, commercialized, regulated, and incorporated into healthcare rather than as stages of a predetermined model.

Biblical Healing and Restoration

Revelation 22:2 provides the biblical point of departure through its association of leaves with "the healing of the nations," paralleling Ezekiel 47:12, where leaves are similarly associated with healing. Because interpretations of Revelation's imagery vary (Mathewson, 2021; Meverden, 2026), this study does not prescribe an exclusively physical, medicinal, spiritual, symbolic, or eschatological meaning. Instead, the biblical lens provides a conceptual and ethical orientation linking nature, healing, restoration, stewardship, and collective well-being without treating Scripture as biomedical evidence.

Traditional and Indigenous Knowledge Systems

Traditional and Indigenous knowledge systems provide a second lens. Across Africa, Asia, and Indigenous communities globally, medicinal knowledge has developed through observation, experience, adaptation, and intergenerational transmission and encompasses plant identification, preparation, therapeutic use, environmental relationships, and cultural understandings of health and illness (Alum, 2024).

Traditional use does not independently establish clinical efficacy or safety, but it can preserve observations capable of generating scientifically relevant therapeutic hypotheses. This perspective therefore distinguishes knowledge recognition from therapeutic validation while acknowledging questions of epistemic justice, attribution, ownership, participation, intellectual property, biodiversity, and equitable benefit sharing when community knowledge contributes to scientific or commercial development.

Phamaceutical Influence and the Political Economy of Medicine

The third perspective examines phamaceutical influence and the political economy of medicine. Phamaceutical influence describes processes through which health and other conditions increasingly become understood or managed through pharmaceutical interventions (Williams et al., 2011). It should be distinguished from pharmaceutical science itself: whereas pharmaceutical research has produced major therapeutic advances, phamaceutical influence directs attention to the institutional and economic forces shaping how medicines are developed, recognized, regulated, and used.

Applied to medicinal plants, this lens examines how research investment, scientific authority, intellectual property, regulation, markets, and commercial incentives influence which traditional therapies are investigated, standardized, patented, approved, and distributed. It also raises questions of who controls medicinal knowledge and who benefits when it acquires scientific or commercial value, connecting pharmaceutical development with bioprospecting, potential biopiracy, community rights, biodiversity, access, and distributive justice. The central concern is therefore not whether pharmaceutical development is inherently beneficial or harmful, but how institutional and economic power shapes the transformation of medicinal knowledge into recognized therapeutic products.

Integrative Healthcare

Integrative healthcare provides the fourth perspective and moves the inquiry beyond treating traditional and pharmaceutical medicine as inherently competing systems. Integration does not imply indiscriminate incorporation of traditional practices or equivalent evidentiary status for all therapies. Rather, it concerns the conditions under which different forms of knowledge and care may interact while maintaining appropriate standards of evidence, safety, quality, professional competence, cultural responsiveness, and patient-centered care.

The WHO *Global Traditional Medicine Strategy 2025–2034* supports this orientation through its emphasis on evidence, regulation, health-system integration, community participation, Indigenous Peoples' rights, biodiversity, sustainability, and health equity (WHO, 2025). However, integration also involves governance and power, particularly when traditional knowledge becomes separated from its cultural context or knowledge holders lose authority over its use. Evidence-informed integration must therefore consider therapeutic effectiveness and safety alongside cultural recognition, participation, autonomy, ownership, access, and equitable benefit sharing.

Together, the four perspectives provide complementary, rather than sequential, lenses for examining medicinal plants, healing knowledge, pharmaceutical power, and contemporary healthcare. They neither presume that traditional medicine should be absorbed into pharmaceutical medicine nor that all traditional therapies warrant clinical integration. Figure 1 illustrates their relationship while preserving these conceptual distinctions.

ISSN 2348-1218 (print)
International Journal of Interdisciplinary Research and Innovations ISSN 2348-1226 (online)
Vol. 14, Issue 3, pp: (106-127), Month: July 2026 - September 2026, Available at: www.researchpublish.com

Figure 1: ***Conceptual and Theoretical Framework for Examining Medicinal Herbs, Pharmaceutical Power, and Integrative Healthcare***



Note. *The framework integrates biblical healing and restoration, traditional and Indigenous knowledge systems, phamaceutical influence and the political economy of medicine, and integrative healthcare as complementary analytical perspectives guiding the review.*

II. METHODOLOGY

This study employed an integrative literature review and conceptual analysis to examine medicinal plants, traditional and Indigenous knowledge, pharmaceutical influence, and evidence-informed integrative healthcare. The design enabled synthesis across scientific, historical, theological, social-science, and policy literature (Snyder, 2019; Whittemore & Knafl, 2005). The four perspectives established in the conceptual foundations served as sensitizing analytical lenses.

Evidence was interpreted according to its disciplinary function. Biblical and theological scholarship informed textual and conceptual analysis; traditional and historical knowledge informed medicinal practices and therapeutic hypotheses; scientific research informed efficacy and safety; and social-science and policy literature informed pharmaceutical influence, governance, equity, and healthcare integration. Traditional use was not equated with clinical efficacy, nor was limited clinical evidence treated as proof of therapeutic ineffectiveness.

Search Strategy and Eligibility Criteria

PubMed/MEDLINE, Scopus, Web of Science, Google Scholar, and the ATLA Religion Database were searched, supplemented by authoritative WHO, FDA, WIPO, and other relevant policy and regulatory sources. Search terms addressed medicinal plants, herbal and traditional medicine, Indigenous knowledge, ethnobotany, ethnopharmacology, natural-product drug discovery, pharmaceutical influence and power, intellectual property, commercialization, safety, regulation, integrative healthcare, Revelation 22:2, Ezekiel 47:12, and *healing of the nations*. Backward and forward citation searching supplemented database retrieval.

Literature published between 2015 and 2026 was prioritized, while relevant seminal, historical, methodological, and biblical sources were retained. Eligible sources included peer-reviewed empirical, review, theoretical, conceptual, historical, and theological literature and authoritative policy and regulatory documents. Commercial or promotional materials, unsourced therapeutic claims, nonauthoritative sources, and substantively irrelevant literature were excluded. Only English-language sources were included.

ISSN 2348-1218 (print)
International Journal of Interdisciplinary Research and Innovations ISSN 2348-1226 (online)
Vol. 14, Issue 3, pp: (106-127), Month: July 2026 - September 2026, Available at: www.researchpublish.com

Evidence Selection, Extraction, and Organization

Search results were consolidated and duplicate records removed before screening. The remaining records were screened by title and abstract for relevance to the research questions and eligibility criteria, followed by full-text assessment of potentially eligible sources. Seminal theoretical, methodological, biblical, and historical works were retained when relevant and were not excluded solely on the basis of publication date. Sources identified through backward and forward citation searching were subjected to the same eligibility criteria as those identified through the primary database search. Following screening and full-text eligibility assessment, 20 sources were retained for the final integrative synthesis. The complete evidence-selection process is presented in Figure 2.

As shown in Figure 2, the search identified 1,465 records, including 1,286 records from bibliographic databases and 179 additional records from other sources. Database records were retrieved from PubMed/MEDLINE (n = 318), Scopus (n = 402), Web of Science (n = 291), and the ATLA Religion Database (n = 96). Additional records were identified through Google Scholar, reference-list searching, forward citation searching, and institutional sources, including materials from the World Health Organization (WHO), U.S. Food and Drug Administration (FDA), and World Intellectual Property Organization (WIPO).

Following consolidation of the search results, 327 duplicate records were removed. Of the 959 records subsequently screened by title and abstract, 708 were excluded because they did not demonstrate sufficient relevance to the research questions. This process resulted in 251 reports sought for full-text retrieval. Thirteen reports could not be retrieved because full texts were unavailable, leaving 238 reports for full-text eligibility assessment.

During full-text assessment, 218 reports were excluded. Reasons for exclusion included insufficient relevance to the study (n = 61), discussion of medicinal plants without sufficient substantive relevance to the research questions (n = 34), insufficient scholarly or evidentiary support (n = 25), duplication or substantial overlap with other included evidence (n = 20), promotional or advocacy-oriented content (n = 14), insufficient relevance to the study's key analytical domains (n = 13), and other eligibility-related reasons (n = 51). The screening and eligibility process therefore resulted in 20 sources included in the final integrative synthesis.

These 20 sources constituted the core evidence set for the formal thematic and conceptual analysis and were selected for their capacity to address the research questions across the study's major areas of inquiry: biblical and historical perspectives on plant-based healing; traditional and Indigenous medicinal knowledge; the contribution of medicinal plants and traditional knowledge to pharmaceutical discovery and development; pharmaceutical influence, commercialization, and intellectual-property considerations; evidence, safety, standardization, and regulation; and the potential role of medicinal plants within evidence-informed integrative healthcare. Additional theoretical, methodological, historical, biblical, regulatory, and contextual references were used elsewhere in the manuscript to support interpretation and background but were not counted among the 20 sources comprising the formal synthesis.

Figure 2. PRISMA 2020 Flow Diagram for the Identification and Selection of Sources



Note. The figure presents the identification, screening, eligibility assessment, and inclusion of sources used in the integrative literature review and conceptual analysis, following the PRISMA 2020 framework (Page et al., 2021).

Data Analysis and Thematic Synthesis

The 20 included sources were analyzed through thematic and conceptual synthesis consistent with the integrative-review design. Analysis involved iterative reading, comparison, coding, and categorization to identify recurring concepts, areas of convergence and disagreement, relationships among knowledge systems, and implications for evidence-informed integrative healthcare.

Initial coding was informed by the four analytical perspectives: biblical healing and restoration, traditional and Indigenous knowledge systems, pharmaceutical influence and the political economy of medicine, and integrative healthcare. These served as sensitizing concepts rather than fixed categories, allowing additional themes and relationships to emerge from the evidence.

Cross-source comparison was used to distinguish among forms of evidence and identify relationships and tensions across disciplines. Particular attention was given to traditional knowledge and scientific validation, medicinal-plant and pharmaceutical development, pharmaceutical influence and commercialization, safety and regulation, intellectual property and benefit sharing, and healthcare integration. Themes were subsequently organized in relation to the five research questions.

III. LITERATURE REVIEW

Medicinal plants occupy a distinctive position at the intersection of history, culture, science, healthcare, and commerce. Long before the development of contemporary pharmaceutical systems, communities identified plants associated with healing and transmitted knowledge concerning their preparation and use. Modern pharmaceutical science subsequently provided increasingly sophisticated methods for investigating biological activity, identifying therapeutic constituents, evaluating toxicity and efficacy, standardizing products, and developing regulated medicines. These developments, however, have also raised questions concerning whose knowledge is recognized, how therapeutic evidence is evaluated, who controls medicinal resources, and how the benefits of pharmaceutical innovation are distributed.

The literature reviewed in this study is therefore organized around five interconnected areas: biblical and historical foundations of plant-based healing; the transition from medicinal plants to pharmaceutical development; evidence, safety, and regulation in herbal and pharmaceutical medicine; pharmaceutical influence and the political economy of medicine; and the conditions supporting evidence-informed integrative healthcare.

Biblical and Historical Foundations of Plant-Based Healing

The biblical point of departure for this study is Revelation 22:2, which describes the tree of life and states that its leaves are “for the healing of the nations.” The imagery has an important textual antecedent in Ezekiel 47:12, where trees growing beside a life-giving river produce fruit for food and leaves for healing. These passages place vegetation, life, provision, restoration, and healing in close conceptual relationship.

The meaning of the healing leaves in Revelation remains open to theological and literary interpretation. Meverden (2026), for example, examines the imagery in relation to restoration, hope, empire, and Roman visual culture while recognizing Revelation's intertextual connections with Genesis and Ezekiel. Such interpretations demonstrate the richness of Revelation 22:2 without requiring a single exclusively physical, medicinal, spiritual, symbolic, or eschatological interpretation.

For the purposes of this study, the significance of the passage lies in its explicit association of leaves with healing and the nations. Scripture is not treated as clinical evidence for the efficacy of particular plants. Rather, Revelation 22:2 provides a conceptual point of departure for examining the broader historical relationship among plants, healing, restoration, stewardship, and human well-being. This relationship becomes particularly relevant when considered alongside the extensive historical evidence that communities across civilizations have identified and used plants for therapeutic purposes.

Other biblical references similarly reflect familiarity with oils, resins, spices, plants, and other natural materials within the social and healing environments of the ancient world. These references should not automatically be interpreted as modern pharmacological prescriptions, but they demonstrate that biblical societies existed within cultural environments in which natural substances were familiar components of human care. Biblical interpretation and biomedical science consequently perform different evidentiary functions while contributing complementary perspectives to an interdisciplinary examination of plants and healing.

Traditional and Indigenous Medicinal Knowledge

Plant-based healing developed across Africa, Asia, the Mediterranean, the Middle East, and Indigenous societies throughout the world. Communities accumulated knowledge through observation, repeated experience, environmental interaction, practitioner expertise, and intergenerational transmission. Some traditions became codified into formal systems of medicine, whereas others remained predominantly oral, community-based, or practitioner-mediated.

Traditional medicinal knowledge should not be understood simply as an undeveloped version of modern pharmacology. It may be embedded within broader understandings of health involving relationships among individuals, families, communities, spirituality, environment, diet, social life, and meaning. Consequently, the significance of medicinal plants within traditional healing systems may extend beyond their chemical constituents alone (Nasim et al., 2022).

Africa represents an especially important context because of its substantial biological diversity, longstanding medicinal-plant traditions, and continuing reliance on traditional practitioners in many communities (Cornelius & Van Wike, 2024). Medicinal knowledge has historically been maintained through healers, families, elders, and community networks and may remain important where conventional health services are geographically, financially, or culturally less accessible. Contemporary African traditional medicine therefore intersects with healthcare access, cultural identity, biodiversity, practitioner competency, regulation, and the preservation of Indigenous knowledge **(**D'Almeida**,** 2024).

Similar relationships between medicinal plants and established healing traditions are evident across Asia. Chinese, Indian, and other Asian medical traditions developed extensive systems for classifying medicinal substances and relating therapeutic preparations to broader understandings of health and disease. Indigenous societies in other regions likewise developed detailed knowledge of locally available plants through sustained relationships with their environments.

These knowledge systems warrant neither automatic clinical acceptance nor categorical dismissal. Traditional use may document repeated therapeutic observations and identify plants worthy of investigation, but historical or cultural use does not independently establish clinical efficacy. Conversely, the absence of contemporary clinical trials does not demonstrate that accumulated observations are scientifically meaningless. Traditional and Indigenous knowledge can therefore function as a source of therapeutic hypotheses while remaining distinct from the scientific evidence required to establish standardized clinical safety and effectiveness (Alum, 2024; World Health Organization [WHO], 2025a).

From Traditional Knowledge to Pharmaceutical Science

The historical relationship between medicinal plants and modern pharmaceuticals is characterized by both continuity and transformation. Natural products and their derivatives have contributed substantially to pharmacotherapy and remain important sources of molecular structures and therapeutic leads for contemporary drug discovery (Atanasov et al., 2021; Wang et al., 2024).

Traditional knowledge has sometimes contributed to this process by directing scientific attention toward plants already associated with particular therapeutic uses. Artemisinin provides a prominent illustration of how knowledge derived from a longstanding medicinal tradition can contribute to the development of a globally important pharmaceutical therapy after extensive scientific investigation. Such examples demonstrate the potential value of traditional knowledge without implying that every historically used remedy will demonstrate clinical effectiveness.

The transition is therefore neither automatic nor universal. Some medicinal plants demonstrate biological activity but lack adequate clinical evidence; others present toxicity, interaction, dosage, quality, or reproducibility concerns; and many have never undergone sufficient investigation. Selected natural products, however, have progressed through scientific characterization, pharmacological investigation, clinical evaluation, standardization, and regulatory review to become established therapies.

The historical relationship between medicinal plants and pharmaceutical medicine is consequently better understood as partially continuous rather than categorically separate. Modern pharmaceutical science introduced increasingly rigorous methods for evaluating therapeutic substances, but medicinal plants and traditional knowledge continue to provide potentially valuable sources of scientific inquiry. This continuity also introduces questions concerning recognition, ownership, commercialization, and whether communities that preserve medicinal knowledge share appropriately in the benefits arising from its scientific and commercial development.

From Medicinal Plants to Modern Pharmaceuticals

The distinction between medicinal plants and pharmaceuticals does not rest simply on whether a therapeutic substance originated in nature. Increasingly, it concerns the processes through which a therapeutic candidate is investigated, characterized, standardized, evaluated, manufactured, regulated, and incorporated into clinical practice (Atanasov et al., 2021; Wang et al., 2024).

From Traditional Knowledge to Scientific Investigation

Medicinal plants may enter scientific investigation through traditional use, ethnobotanical documentation, ecological observations, laboratory screening, chemical characteristics, or systematic natural-product research. Traditional medicinal knowledge is therefore an important potential source of therapeutic leads, although it is not the only pathway through which natural products enter pharmaceutical research.

Ethnopharmacology provides an important interface between culturally accumulated medicinal knowledge and botanical, chemical, pharmacological, toxicological, and clinical investigation. Repeated use of a particular plant for a health condition may provide a therapeutic hypothesis. Scientific investigation can subsequently determine botanical identity, chemical composition, biological activity, mechanisms, dosage, toxicity, interactions, and potential clinical effectiveness.

These forms of knowledge perform different functions. Traditional observation may identify a therapeutic possibility, whereas claims concerning standardized clinical safety and effectiveness require additional scientific evidence. Requiring such evidence does not negate the historical contribution of knowledge holders whose observations may have directed scientific attention toward a medicinal resource.

Characterization, Standardization, and Evaluation

Scientific investigation of medicinal plants may involve botanical authentication, extraction, phytochemical characterization, biological screening, pharmacological testing, toxicological evaluation, and clinical research. Natural products can be chemically complex, and their biological effects may arise from individual constituents, metabolites, multiple active compounds, or interactions among components (Atanasov et al., 2021).

Such complexity makes standardization particularly important. Botanical composition may vary according to species, genetics, geographic origin, climate, soil, cultivation, harvesting, plant part, storage, processing, extraction, and manufacturing. Products carrying the same common plant name may therefore differ substantially in chemical composition and biological activity. Reliable botanical medicines consequently require validated approaches to identity, composition, quality, and reproducibility (Indrayanto, 2022; Wang, 2024).

Scientific evaluation must also distinguish biological activity from clinical efficacy. Laboratory or preclinical activity may justify further investigation but does not establish therapeutic benefit in humans. Clinical claims require evidence appropriate to the intended use, while safety evaluation must consider toxicity, dosage, contraindications, interactions, vulnerable populations, and consequences of treatment failure.

From Botanical Product to Regulated Medicine

Regulated pharmaceutical development adds requirements involving reproducible manufacturing, quality assurance, clinical evidence, labeling, pharmacovigilance, and regulatory oversight. Botanical origin does not inherently prevent a therapeutic product from becoming a regulated pharmaceutical medicine. Rather, botanical complexity may require specialized approaches to characterization, manufacturing controls, batch consistency, and clinical evaluation.

The U.S. Food and Drug Administration recognizes botanical drug products derived from plant materials and other specified natural sources when developed for disease-related therapeutic purposes. Contemporary botanical-drug regulation illustrates that the scientifically meaningful boundary is not simply “natural” versus “pharmaceutical,” but whether a therapeutic product satisfies appropriate requirements for identity, quality, safety, effectiveness, reproducibility, manufacturing, and clinical application (Food and Drug Administration [FDA], 2026).

The transition from medicinal plant to pharmaceutical medicine should therefore be understood as a continuum rather than a single threshold. A plant may progress from traditional observation to systematic investigation, characterization, standardization, clinical evaluation, manufacturing, regulatory approval, and pharmacovigilance. Not every medicinal plant completes this progression, nor must every traditional preparation become a pharmaceutical product to possess cultural or therapeutic significance.

From Traditional Knowledge to Pharmaceutical Development

Scientific transformation can alter more than the physical form of a medicinal substance. Knowledge initially maintained within communities, families, or healing traditions may enter universities, laboratories, regulatory agencies, pharmaceutical companies, intellectual-property systems, and global markets. A locally known therapeutic resource can thereby acquire new forms of scientific authority and commercial value (Alum, 2024; World Intellectual Property Organization [WIPO], 2024).

This transformation can produce substantial benefits, including improved characterization, dosage determination, quality control, clinical evaluation, manufacturing consistency, scalability, and wider therapeutic availability. It can also change who possesses authority over the knowledge, who owns resulting innovations, and who receives economic benefits.

The distinction between traditional and pharmaceutical medicine consequently concerns more than the physical origin of a therapeutic substance. It increasingly concerns evidence, characterization, standardization, reproducibility, regulation, manufacturing, ownership, and clinical application. This relationship provides an important bridge between the scientific development of medicinal plants and broader questions concerning evidence, safety, institutional authority, and pharmaceutical influence.

Herbal Medicine and Pharmaceutical Medicine: Evidence, Safety, and Regulation

Debates surrounding herbal and pharmaceutical medicine are frequently presented as a contest between “natural” and “scientific” approaches. Such a binary is inadequate. Herbal therapies vary considerably in evidence, composition, preparation, safety, and intended use, just as pharmaceutical interventions differ in effectiveness, risk, accessibility, and clinical value. The more relevant questions concern the strength of therapeutic evidence, product quality, patient risk, appropriate regulation, and the clinical context in which a therapy is used.

Evidence and Therapeutic Claims

Evidence concerning medicinal plants comes from multiple sources, including historical documentation, traditional use, ethnobotanical research, phytochemical analysis, laboratory studies, toxicological investigations, observational research, clinical trials, effectiveness studies, and pharmacovigilance. Each contributes valuable knowledge, but the different forms of evidence should be interpreted according to what they can reasonably establish.

Traditional and Indigenous use can provide important knowledge about medicinal plants, their preparation, applications, and observed effects across generations. Such knowledge can also guide scientific investigation and the identification of potentially useful therapeutic compounds. However, traditional use alone does not establish clinical efficacy. Similarly, evidence of biological activity in laboratory or animal studies may demonstrate therapeutic potential without establishing that the same effects will occur safely and effectively in humans. Clinical research is therefore important for determining efficacy, appropriate use, dosage, interactions, adverse effects, and other considerations relevant to patient care.

The strength of evidence needed also depends on the nature of the therapeutic claim and the potential consequences of its use. Claims concerning general health and well-being differ substantially from claims that a medicinal plant can prevent, manage, or treat serious conditions such as cancer, malaria, diabetes, or cardiovascular disease. More consequential therapeutic claims require stronger clinical evidence, clearer safety information, and appropriate regulatory oversight.

A balanced approach therefore recognizes the contribution of traditional knowledge and emerging scientific evidence while applying appropriate evidentiary standards to clinical claims. This allows medicinal plants to be investigated and potentially incorporated into healthcare without either dismissing longstanding therapeutic knowledge or presenting preliminary findings as established clinical evidence.

Whole-Plant Preparations, Standardization, and Quality

A continuing issue concerns whether the therapeutic properties of medicinal plants are best represented by whole-plant preparations or isolated compounds. Pharmaceutical development has often emphasized identifiable constituents whose pharmacological effects, dosage, metabolism, toxicity, and clinical performance can be characterized. This approach offers substantial advantages for reproducibility and dosage control (Atanasov et al., 2021; Wang et al., 2024).

Whole-plant preparations may contain multiple biologically active constituents whose interactions can be synergistic, additive, antagonistic, or clinically insignificant. Chemical complexity does not establish therapeutic superiority, but neither does it make botanical therapies inherently unsuitable for scientific evaluation. The relevant question is whether a particular preparation can be sufficiently characterized and controlled to support the therapeutic claim being advanced.

Quality therefore depends on accurate botanical identification, validated manufacturing processes, contamination and adulteration controls, appropriate storage, labeling, and batch consistency (Raclariu-Manolică et al., 2023). Standardization should provide sufficient reproducibility for safe and reliable use while recognizing the distinctive chemical complexity of botanical preparations (Indrayanto, 2024; Wang et al., 2023).

Safety and Herb–Drug Interactions

The assumption that "natural" means safe is scientifically untenable. Medicinal plants contain biologically active substances capable of producing therapeutic effects, adverse effects, toxicity, allergic reactions, contraindications, and interactions with pharmaceutical drugs (Cheng et al. 2023). Risk may also arise from incorrect species identification, contamination, adulteration, inappropriate dosage, poor manufacturing, or substitution of inadequately supported therapies for effective treatment.

Herb–drug interactions are particularly important because patients may use traditional remedies, dietary supplements, and prescription medicines simultaneously without informing healthcare professionals. Pharmacovigilance systems should therefore include herbal and traditional medicines, and clinical encounters should encourage respectful disclosure of medicinal-plant use. This is particularly strong because it synthesizes 26 studies using pharmacovigilance databases and found substantial variation and limitations in adverse-event reporting (Kongkaew et al., 2024).

Safety requires responsibilities across healthcare systems. Conventional clinicians need sufficient knowledge to recognize potentially significant herbal risks and interactions, while traditional practitioners require mechanisms for recognizing clinical warning signs, referring patients appropriately, and understanding important interactions with conventional therapies. Patient safety should remain a nonnegotiable condition of integration.

Regulation and Clinical Integration

Regulatory approaches to herbal and traditional medicines vary substantially across countries and product categories. A preparation may be classified as a medicine in one jurisdiction, a supplement in another, or a traditional product under a separate regulatory pathway. Such fragmentation creates differences in evidence requirements, manufacturing standards, labeling, practitioner oversight, and post-market surveillance. (Kongkaew et al., 2024). Different products and uses may justify different pathways. Nevertheless, comparable expectations concerning identity, quality, safety, truthful claims, accountability, and patient protection remain necessary.

WHO's *Global Traditional Medicine Strategy 2025–2034* emphasizes strengthening the evidence base, improving quality and safety through appropriate regulation, and facilitating responsible integration of traditional, complementary, and integrative medicine into health systems (WHO, 2025a). Regulation can therefore function as a bridge between medicinal knowledge and clinical practice by protecting the public from unsafe or unsupported products while creating credible pathways for sufficiently supported therapies.

Beyond the Herbal–Pharmaceutical Dichotomy

The literature does not support categorical acceptance or rejection of either herbal or pharmaceutical medicine. Two opposing errors are particularly important to avoid. The first is uncritical acceptance, assuming that natural, ancient, Indigenous, or traditional origin establishes safety and effectiveness. The second is epistemic dismissal, assuming that knowledge developed outside contemporary biomedical institutions lacks scientific or therapeutic value.

A more defensible position recognizes traditional medicinal knowledge as a potentially valuable source of therapeutic insight while requiring evidence proportionate to the intended clinical claim and risk. Likewise, pharmaceutical therapies should be evaluated according to evidence, safety, therapeutic value, affordability, and accessibility rather than assumed to be superior merely because they have entered institutional medicine.

The meaningful distinction is therefore not simply herbal versus pharmaceutical, but among therapies differing in quality of evidence, product consistency, risk, clinical applicability, and regulatory oversight.

Pharmaceutical Influence and the Political Economy of Medicine

Medicines exist within economic, scientific, institutional, and political systems that influence which therapies are investigated, recognized, manufactured, regulated, prescribed, and made accessible. Williams et al. (2011) use the concept of pharmaceuticalization to describe the expansion of pharmaceutical approaches to human conditions. In the present analysis, this concept provides a basis for examining pharmaceutical influence without treating pharmaceutical science itself as inherently problematic.

Pharmaceutical science has produced substantial improvements in therapeutic discovery, clinical evaluation, manufacturing consistency, quality assurance, and pharmacovigilance. Critical analysis is therefore directed not at pharmaceutical science as such, but at how commercial incentives, institutional authority, intellectual property, markets, and regulatory structures can influence therapeutic knowledge and access.

Commercial Interests and Research Priorities

Drug development requires substantial scientific, financial, regulatory, and manufacturing resources. Commercial investment can enable therapies to progress from laboratory investigation to clinical use, but investment decisions are also influenced by expected markets, intellectual-property protection, development costs, regulatory requirements, and anticipated returns.

These incentives can influence which therapeutic candidates receive extensive investigation. Medicinal plants or traditional practices with limited commercial potential may consequently receive less research attention even when preliminary observations warrant further investigation. Conversely, commercial development does not itself establish therapeutic superiority.

The absence of extensive research should therefore be distinguished from evidence demonstrating ineffectiveness. Likewise, commercialization should not be confused with proof of greater clinical value. Research priorities reflect interactions among scientific promise, public-health need, institutional capacity, commercial incentives, and policy.

Scientific Authority and Recognition of Knowledge

Contemporary healthcare appropriately gives substantial authority to scientific evidence because systematic investigation can evaluate efficacy, toxicity, dosage, mechanisms, interactions, and reproducibility. However, scientific institutions also influence what becomes researched, published, regulated, reimbursed, prescribed, and taught within professional education.

This creates an important distinction between knowledge recognition and therapeutic validation. Recognition acknowledges that communities or practitioners may have identified medicinal species, preparations, and therapeutic observations before contemporary scientific investigation. Validation determines whether particular therapeutic claims are supported sufficiently for clinical use.

The two processes should not be conflated. Recognizing the origin of knowledge does not exempt therapeutic claims from scientific evaluation, while requiring scientific validation does not require erasing the historical or cultural origins of the knowledge being investigated (Alum, 2024).

Intellectual Property, Bioprospecting, and Benefit Sharing

Questions of ownership become particularly important when traditional knowledge or genetic resources contribute to commercially valuable innovation. Intellectual-property protections can encourage research and development, but difficulties arise when inventions depend partly on knowledge maintained by Indigenous Peoples or local communities.

Bioprospecting can contribute to drug discovery, scientific research, conservation, and economic development when conducted ethically. Concerns about biopiracy arise when biological resources or associated traditional knowledge are appropriated or commercialized without adequate authorization, attribution, participation, or equitable compensation.

The *WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge*, adopted in 2024, represents an important development in addressing the relationship among intellectual property, genetic resources, and associated traditional knowledge. Upon entry into force and under specified conditions, the treaty establishes disclosure requirements for qualifying patent applications involving genetic resources or associated traditional knowledge (WIPO, 2024).

Responsible medicinal-plant development should therefore consider prior informed consent where applicable, attribution, community participation, intellectual-property governance, and equitable benefit sharing. Communities should not be treated merely as repositories from which commercially useful biological resources and medicinal knowledge can be extracted.

Markets, Access, and Equity

Commercialization can transform a medicinal resource into a standardized therapy capable of large-scale production and distribution. At the same time, patents, market exclusivity, manufacturing concentration, pricing, supply chains, procurement systems, and national purchasing capacity can influence who ultimately receives access.

These issues are particularly significant when medicinal resources or associated knowledge originate in lower-income settings while resulting products are developed, patented, manufactured, or marketed elsewhere. The relevant policy question is therefore not whether intellectual-property protection should simply exist or disappear, but how innovation incentives can coexist with equitable access.

Public investment, licensing arrangements, technology transfer, regional manufacturing, procurement strategies, affordability measures, and benefit-sharing mechanisms can help align pharmaceutical innovation with public-health needs. An equitable political economy of medicine should seek to connect innovation with access, intellectual property with responsibility, and commercialization with fair distribution of benefits.

Biodiversity and Stewardship

Medicinal plants are biological as well as therapeutic resources. Habitat loss, climate change, overharvesting, unsustainable cultivation, and commercial exploitation may threaten medicinal species and the ecological systems supporting them. The loss of medicinal biodiversity may simultaneously contribute to the disappearance of associated traditional knowledge (Davis, & Choisy, 2024).

WHO's contemporary traditional-medicine strategy explicitly recognizes biodiversity, sustainability, cultural respect, and Indigenous Peoples' rights as relevant to the future of traditional medicine (WHO, 2025a). Stewardship therefore requires conservation, sustainable harvesting and cultivation, responsible sourcing, and protection of associated ecological knowledge.

An equitable political economy of medicinal plants must consequently consider not only who owns and profits from therapeutic innovation but whether the biological and cultural resources supporting that innovation are preserved. Scientific development, commercial use, biodiversity protection, and community rights should therefore be addressed as interconnected rather than separate concerns.

Evidence-Informed Integrative Healthcare

The literature suggests that neither uncritical acceptance of traditional medicine nor exclusive reliance on pharmaceutical approaches provides an adequate basis for medicinal-plant healthcare. Traditional and Indigenous knowledge can identify therapeutic possibilities and preserve culturally meaningful approaches to healing, while scientific and pharmaceutical systems provide essential mechanisms for evaluating efficacy and risk, improving product consistency, and supporting clinical application. The challenge is to bring these contributions into productive relationship while maintaining scientific rigor, patient safety, cultural respect, ethical governance, and equitable access (WHO, 2025a).

Recognition and Scientific Validation of Traditional Knowledge

Responsible integration requires recognition of traditional and Indigenous medicinal knowledge without equating recognition with demonstrated clinical efficacy. Recognition acknowledges knowledge holders, preserves potentially valuable therapeutic observations, and supports appropriate investigation. Scientific validation addresses a different question: whether a particular therapy possesses sufficient evidence of identity, quality, safety, and effectiveness for its intended clinical use.

Ethnobotanical knowledge can identify promising species and therapeutic hypotheses, but clinical application may require further investigation of chemical characteristics, biological activity, toxicity, interactions, dosage, and effectiveness (Atanasov et al., 2021; Wang et al., 2024). Evidence requirements should remain proportionate to therapeutic claims and potential risks.

Scientific validation and epistemic recognition can therefore operate together. Scientific methods can evaluate therapeutic claims without assuming that knowledge began only when it entered a laboratory, while recognition of traditional knowledge need not lower standards required to protect patients.

Quality, Safety, and Pharmacovigilance

No approach to integration is credible without reliable quality and safety systems. Medicinal-plant products require controls appropriate to their intended use, including botanical authentication, manufacturing quality, contamination testing, accurate labeling, storage, and product consistency (Indrayanto, 2024).

Safety oversight should continue after products enter clinical or widespread community use. Pharmacovigilance should include herbal and traditional medicines so that adverse events and herb–drug interactions can be detected and evaluated. Patients should be encouraged to disclose traditional and herbal remedies during clinical encounters, and healthcare professionals should be prepared to discuss such use respectfully.

Integration also requires communication and referral between conventional and traditional practitioners where both participate in patient care. Bidirectional competency is preferable to assuming that only one healing system must adapt to the other.

Ethical Pharmaceutical Innovation and Benefit Sharing

Pharmaceutical science can transform medicinal-plant discoveries into standardized and scalable therapies through characterization, formulation, clinical testing, manufacturing controls, and regulatory evaluation (Atanasov et al., 2021; Wang et al., 2024). Such development can improve reliability, accessibility, and therapeutic usefulness.

Scientific development, however, should not unnecessarily erase the knowledge pathways contributing to discovery. When community knowledge or genetic resources contribute materially to commercial innovation, appropriate attribution, intellectual-property governance, community participation, prior informed consent where applicable, and equitable benefit sharing become important ethical considerations (WIPO, 2024).

Benefits need not be exclusively financial. Depending on context, they may include attribution, community health investment, research infrastructure, education, employment, technology transfer, conservation support, or improved access to resulting therapies. Pharmaceutical innovation can therefore contribute to integrative healthcare while remaining accountable to the communities and resources that contribute to discovery.

Patient-Centered and Culturally Responsive Care

The purpose of integration is ultimately improved health rather than preservation of particular medical systems for their own sake. Patients should therefore remain central to therapeutic decisions.

Patient-centered integration requires informed decision-making, communication about evidence and uncertainty, respect for cultural preferences, and protection from unsupported claims. Patients should neither be pressured to abandon culturally meaningful practices without justification nor encouraged to substitute inadequately supported therapies for treatments with demonstrated benefit.

Culturally responsive care also recognizes that understandings of healing may include family, community, spirituality, relationships, environment, and meaning. Contemporary healthcare need not adopt every traditional explanatory system to recognize that these dimensions may influence patient experience, trust, adherence, and therapeutic decision-making.

Health-System Integration and Governance

Integration involves more than making traditional and conventional therapies available within the same healthcare system. Patients may already use both forms of care, sometimes without informing their healthcare providers. When communication and coordination are limited, this can increase the risk of herb–drug interactions, contraindications, incomplete clinical information, and delays in receiving appropriate care.

WHO recognizes that traditional, complementary, and integrative medicine can be incorporated into health systems through different approaches, including people-led, practitioner-led, coordinated, and blended models. The appropriate approach may vary according to cultural context, healthcare infrastructure, regulatory capacity, practitioner systems, financing, and population needs.

Effective integration requires systems that support patient safety and coordinated care. These include appropriate governance and regulation, competent practitioners, communication and referral mechanisms, quality assurance, pharmacovigilance, reliable information, community participation, and ongoing evaluation of health outcomes. Regulation should protect patients from unsafe, poor-quality, or unsupported products while allowing appropriately supported traditional therapies to be considered for responsible use within healthcare.

Evidence-informed integration does not require traditional and conventional therapies to be treated identically. Rather, each therapy should be considered according to the available evidence, its intended use, safety profile, quality, and potential benefits and risks. Traditional and Indigenous knowledge can provide an important foundation for identifying and investigating medicinal practices, while scientific evaluation can help determine their safety, effectiveness, appropriate application, and potential role in contemporary healthcare.

From this perspective, medicinal herbs and pharmaceuticals need not be viewed as inherently opposing approaches to healthcare. More important considerations include how therapeutic knowledge is recognized and evaluated, the strength of available evidence, patient safety, pharmaceutical and institutional influence, ownership and benefit sharing, and the conditions under which plant-based therapies can responsibly contribute to integrative healthcare.

IV. RESULTS

The thematic and conceptual synthesis of the 20 included sources identified five interrelated findings corresponding to the research questions. Collectively, the evidence demonstrates historical continuity in medicinal-plant knowledge, important contributions of traditional knowledge to pharmaceutical discovery, substantial institutional and commercial influences on therapeutic recognition, persistent scientific and regulatory challenges in herbal medicine, and emerging conditions for evidence-informed integration.

RQ1: How have biblical, historical, traditional, and cross-cultural understandings of medicinal plants contributed to concepts and practices of healing?

The synthesis indicates that medicinal plants have occupied enduring roles in human understandings and practices of healing across biblical, African, Asian, Indigenous, and other historical traditions. Revelation 22:2 and its relationship to Ezekiel 47:12 provide a biblical association among vegetation, healing, restoration, and collective well-being without constituting biomedical evidence for specific therapies. Across cultures, medicinal knowledge developed through observation, experience, environmental interaction, practitioner knowledge, and intergenerational transmission.

The evidence further indicates that traditional medicinal knowledge encompasses more than plant use alone; it is frequently embedded within broader cultural, ecological, relational, and spiritual understandings of health. Historical use does not establish contemporary clinical efficacy, but it represents an accumulated knowledge resource capable of generating therapeutic hypotheses and informing scientific investigation. RQ1 therefore demonstrates that medicinal-plant knowledge has contributed substantially to historical concepts and practices of healing while requiring appropriate distinction between cultural or historical use and scientifically demonstrated therapeutic effectiveness.

How has traditional medicinal knowledge contributed to the discovery, scientific investigation, and pharmaceutical development of plant-derived therapies?

The evidence indicates that traditional medicinal knowledge has contributed to pharmaceutical development by identifying plants, preparations, and therapeutic uses worthy of scientific investigation. Ethnobotanical and ethnopharmacological knowledge can generate therapeutic leads that subsequently undergo botanical authentication, chemical characterization, pharmacological investigation, toxicity assessment, standardization, clinical evaluation, manufacturing, and regulatory review.

The development of artemisinin illustrates this relationship, demonstrating how knowledge originating within a traditional healing system can contribute to a scientifically validated pharmaceutical therapy. However, the pathway is neither automatic nor universal: many traditional remedies remain insufficiently investigated, fail to demonstrate clinical effectiveness, present safety concerns, or are unsuitable for pharmaceutical development. RQ2 therefore indicates that traditional knowledge and pharmaceutical science are neither identical nor inherently opposing systems. Traditional knowledge may identify therapeutic possibilities, while scientific investigation determines whether and under what conditions those possibilities can become safe, effective, reproducible, and clinically applicable therapies.

RQ3: How do pharmaceutical influence, commercial interests, intellectual-property systems, regulatory structures, and institutional authority influence the recognition, development, ownership, and accessibility of medicinal-plant therapies?

The synthesis demonstrates that therapeutic recognition is shaped not only by pharmacological properties but also by research investment, scientific institutions, regulatory systems, intellectual-property arrangements, markets, professional authority, and commercial incentives. Pharmaceutical development can provide important mechanisms for scientific evaluation, quality assurance, manufacturing, distribution, and pharmacovigilance, but institutional and economic structures also influence which therapeutic possibilities receive research attention and commercial development.

Traditional and Indigenous medicinal knowledge raises additional questions of attribution, ownership, prior informed consent, intellectual property, bioprospecting, potential biopiracy, and equitable benefit sharing when community knowledge or biological resources contribute to commercially valuable innovation. RQ3 therefore indicates that pharmaceutical power should be understood not simply as the existence of pharmaceutical products but as the institutional and economic capacity to influence what is researched, validated, regulated, commercialized, and made accessible as recognized medicine.

RQ4: What scientific, safety, ethical, cultural, and regulatory challenges affect the incorporation of herbal medicine into contemporary healthcare?

The evidence identifies interconnected challenges involving uneven evidence, botanical variability, product identity and standardization, toxicity, herb–drug interactions, contamination and adulteration, regulatory fragmentation, practitioner competency, unsupported commercial claims, biodiversity, and protection of traditional knowledge. These challenges demonstrate that natural or traditional origin cannot substitute for appropriate evidence of quality, safety, and effectiveness.

At the same time, insufficient contemporary research should not automatically be interpreted as evidence of ineffectiveness. The appropriate evidentiary requirement depends on the therapeutic claim, potential risk, and consequences of treatment failure. Responsible incorporation therefore requires proportionate scientific evaluation, quality assurance, pharmacovigilance, professional communication, cultural recognition, and appropriate regulatory oversight. RQ4 shifts the question from whether herbal medicine should be accepted or rejected categorically to what evidence and safeguards are required for particular therapies and clinical applications.

RQ5: How can traditional medicinal knowledge, scientific validation, pharmaceutical innovation, ethical governance, and equitable benefit sharing contribute to evidence-informed integrative healthcare?

The synthesis identifies several interrelated conditions for responsible integration: recognition of traditional and Indigenous knowledge; appropriate scientific investigation and validation; reliable quality and safety systems; ethical pharmaceutical innovation; equitable benefit sharing; biodiversity stewardship; patient-centered and culturally responsive care; and health-system capacity for regulation, communication, referral, and pharmacovigilance.

Integration therefore does not mean indiscriminate incorporation of traditional therapies into biomedical healthcare. Rather, it involves bringing potentially complementary forms of knowledge and care into structured relationship while maintaining standards appropriate to therapeutic claims and risks. Traditional knowledge can identify therapeutic possibilities; scientific investigation can evaluate them; pharmaceutical science can support characterization, standardization, and scalable development; governance can protect patients and knowledge holders; and health systems can provide mechanisms for safe and culturally responsive clinical use.

Collectively, the findings support an evidence-informed approach to integrative healthcare in which traditional knowledge, scientific validation, pharmaceutical innovation, ethical governance, ecological stewardship, and patient-centered care operate as complementary considerations while remaining subject to appropriate standards of evidence, safety, equity, and accountability.

V. DISCUSSION

This integrative review examined relationships among medicinal plants, traditional and Indigenous knowledge, pharmaceutical development, institutional and commercial power, and evidence-informed integrative healthcare. Viewed through the four-lens conceptual framework, biblical healing and restoration, traditional and Indigenous knowledge systems, phamaceutical influence and the political economy of medicine, and integrative healthcare—the findings challenge

the conventional opposition between herbal and pharmaceutical medicine. Medicinal-plant knowledge has deep historical and cross-cultural foundations; natural products have contributed substantially to pharmaceutical innovation; scientific and regulatory systems provide essential mechanisms for evaluating therapeutic claims and protecting patients; and institutional and economic structures influence which knowledge becomes investigated, recognized, regulated, commercialized, and accessible.

The central implication is not that healthcare should return to traditional medicine or move further away from it. Rather, healthcare systems need mechanisms for recognizing potentially valuable medicinal knowledge, investigating it rigorously, protecting patients, respecting knowledge holders, governing commercialization ethically, and integrating appropriately supported therapies.

Healing, Nature, and the Meaning of the Biblical Point of Departure

Revelation 22:2 associates leaves with the "healing of the nations" within a broader vision of restoration and renewed well-being and echoes the healing imagery of Ezekiel 47:12. This review does not attempt to resolve whether these passages should be understood physically, medicinally, spiritually, symbolically, eschatologically, or through some combination of meanings. Nor is Scripture treated as pharmacological evidence. Rather, the biblical material provides an interdisciplinary point of departure for considering relationships among nature, healing, restoration, stewardship, and collective well-being.

Historical evidence demonstrates that associations between plants and healing extend across African, Asian, Indigenous, and other traditions. The significance of the biblical lens therefore lies not in converting theological claims into biomedical evidence but in placing contemporary debates about medicinal plants within a much longer human engagement with nature and healing. Theological interpretation, traditional knowledge, and biomedical science retain distinct evidentiary functions while contributing different perspectives to the broader discussion.

Traditional Knowledge as a Source of Therapeutic Possibility

Traditional medicinal knowledge should not be understood merely as a historical precursor displaced by modern medicine. It remains a living cultural resource and can provide therapeutic hypotheses for ethnobotanical, ethnopharmacological, and natural-product research. The continuing contribution of natural products to drug discovery, including historically significant cases such as artemisinin, further complicates categorical distinctions between "traditional" and "modern" medicine (Atanasov et al., 2021; Wang et al., 2024).

Recognition, however, must be distinguished from validation. Communities may deserve recognition for identifying, developing, and preserving medicinal knowledge without that recognition establishing the clinical efficacy of every associated therapy. Scientific investigation remains necessary to evaluate specific therapeutic claims. This distinction offers an important resolution to the epistemic tension identified in the review: scientific validation need not erase prior knowledge, and recognition of traditional knowledge need not exempt therapeutic claims from rigorous evaluation.

Pharmaceutical Science and Phamaceutical influence Are Not the Same

A second important distinction concerns pharmaceutical science and phamaceutical influence. Pharmaceutical science provides indispensable mechanisms for characterization, dosage determination, clinical evaluation, manufacturing quality, regulation, and pharmacovigilance. These protections should not be weakened simply because a therapeutic substance originates from a natural or traditional source.

Phamaceutical influence concerns a different issue: the broader institutional, professional, economic, and cultural processes through which pharmaceutical interventions acquire authority within healthcare (Williams et al., 2011). Applied to medicinal plants, this perspective demonstrates that pharmaceutical development is influenced not only by therapeutic potential but also by research funding, intellectual property, regulatory pathways, commercial incentives, and professional authority.

Accordingly, absence of pharmaceutical development does not establish therapeutic ineffectiveness, just as commercial success does not establish comparative clinical superiority. The challenge is to preserve the scientific strengths of pharmaceutical development while critically examining whether innovation systems adequately balance scientific advancement, public-health need, affordability, knowledge recognition, and equitable distribution of benefits.

Knowledge, Ownership, and Epistemic Justice

The transformation of traditional medicinal knowledge into commercially valuable therapies raises questions of ownership and epistemic justice. Community knowledge may be collectively developed and transmitted across generations, whereas contemporary intellectual-property systems generally operate through legally defined inventions and ownership. Tensions arise when traditional knowledge contributes to identifying therapeutic resources that are subsequently characterized, patented, or commercialized.

Recent international developments indicate growing recognition of this problem. The 2024 *WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge* strengthens attention to genetic resources and associated traditional knowledge within patent governance, while the WHO *Global Traditional Medicine Strategy 2025–2034* emphasizes Indigenous Peoples' rights, community participation, cultural respect, biodiversity, evidence, and regulation (World Health Organization [WHO], 2025; World Intellectual Property Organization [WIPO], 2024).

The broader principle is that scientific transformation should not require historical erasure. Researchers and pharmaceutical developers may contribute substantially to converting medicinal observations into safe and clinically useful therapies while still recognizing communities whose knowledge materially informed discovery. Epistemic justice therefore concerns not equal scientific status for all claims, but fairness in whose observations are investigated, whose contributions are acknowledged, who participates in research, and who benefits from commercialization.

Patient Safety as a Nonnegotiable Basis for Integration

The findings also establish clear limits to uncritical incorporation of herbal medicine. Traditional origin, longevity of use, and natural composition do not independently establish safety or clinical effectiveness. Product variability, contamination, dosage uncertainty, herb–drug interactions, and practitioner competency remain legitimate patient-safety concerns.

Evidence and regulation should therefore not be characterized simply as mechanisms of biomedical exclusion. Botanical authentication, quality assurance, toxicity assessment, appropriate clinical evaluation, accurate labeling, pharmacovigilance, and practitioner competency are necessary protections. At the same time, regulatory requirements should be proportionate to therapeutic claims and risks.

This supports a principle of regulatory pluralism without regulatory relativism: different therapeutic products may warrant different evaluative pathways, but patient safety, truthful claims, adequate quality, and evidence appropriate to clinical risk remain fundamental expectations.

Moving Beyond the Herbal–Pharmaceutical Dichotomy

Taken together, the findings demonstrate that treating herbal and pharmaceutical medicine as inherently opposing systems is conceptually inadequate. Pharmaceuticals can originate from plants; botanical preparations can become regulated medicines; traditional knowledge can generate scientific hypotheses; and pharmaceutical technologies can improve the consistency and safety of plant-derived therapies.

The more meaningful distinction is therefore not simply herbal versus pharmaceutical, but among therapies differing in quality of evidence, product consistency, risk, clinical applicability, and regulatory oversight.

This reframing also permits symmetrical scrutiny of commercial interests. Pharmaceutical companies may influence markets and research priorities, while herbal and wellness industries can similarly make unsupported claims or commercialize perceptions associated with “natural” and “traditional” products. Neither tradition nor scientific authority should function as an automatic guarantee of therapeutic legitimacy. Traditional knowledge warrants appropriate recognition and investigation, while clinical recommendations require evidence proportionate to their consequences.

Implications for Evidence-Informed Integrative Healthcare

The findings indicate that meaningful integration requires more than allowing herbal and pharmaceutical therapies to coexist. It requires coordinated relationships among knowledge holders, researchers, regulators, traditional practitioners, clinicians, pharmacists, communities, and patients. WHO's contemporary strategy and health-system integration framework support this direction by combining evidence and regulation with people-centered care, cultural recognition, Indigenous rights, biodiversity, community participation, and multiple models of integration (WHO, 2025).

The present review extends this policy direction by emphasizing interdependent conditions for responsible integration: recognition of traditional knowledge, proportionate scientific investigation, quality and safety assurance, pharmacovigilance, ethical commercialization, equitable benefit sharing, biodiversity stewardship, practitioner competency, patient-centered decision-making, and effective governance. These conditions should not be understood as a rigid pathway. Scientific investigation may confirm some traditional observations, modify others, and determine that some are ineffective or unsafe. A credible integrative healthcare system must accommodate all three outcomes.

Reconsidering the "Healing of the Nations" in Contemporary Healthcare

The phrase "healing of the nations" provides an appropriate interdisciplinary return to the paper's biblical point of departure. The evidence does not require Revelation 22:2 to be interpreted exclusively as either a prescription for medicinal plants or a symbolic statement unrelated to physical healing. Rather, the passage invites consideration of relationships among nature, healing, restoration, and collective well-being.

Contemporary healthcare gives these relationships new expression. Medicinal biodiversity can contribute to therapeutic discovery; traditional knowledge can inform scientific investigation; pharmaceutical science can transform natural products into reliable therapies; and regulatory and health systems can facilitate safe integration. Yet these same processes can produce exploitation, ecological damage, exclusion, or inequitable access when governance is inadequate.

The contemporary significance of "healing of the nations" therefore lies partly in the questions it brings into focus: Are healing resources stewarded responsibly? Is medicinal knowledge treated justly? Does scientific innovation serve human need? Are commercial benefits distributed equitably? Do healthcare systems protect both patient safety and human dignity? These questions connect the paper's biblical point of departure with its central conclusion: the future of medicinal-plant healthcare should move beyond the herbal–pharmaceutical divide toward scientifically rigorous, ethically governed, culturally respectful, and equitable approaches to healing.

This review makes three principal contributions. First, it brings biblical conceptions of healing, traditional and Indigenous medicinal knowledge, pharmaceutical political economy, and integrative healthcare into a single analytical conversation through the four-lens conceptual framework. These domains are often examined separately, limiting understanding of the historical, scientific, ethical, cultural, and institutional relationships among them.

Second, the analysis reframes the herbal–pharmaceutical debate. Rather than asking which system should prevail, the findings support evaluation of specific therapies according to the quality of evidence, therapeutic purpose, safety, product integrity, cultural context, and ethical conditions under which knowledge is developed and commercialized.

Third, the review identifies a set of evidence-derived principles for advancing evidence-informed integrative healthcare without requiring either the displacement of traditional knowledge or the weakening of scientific standards. Recognition and validation, cultural respect and patient safety, pharmaceutical innovation and equitable benefit sharing, and medicinal-resource utilization and biodiversity stewardship are presented not as competing objectives but as responsibilities that must be reconciled within future healthcare systems.

In this respect, the study's principal contribution is not the creation of another medical system positioned between herbal and pharmaceutical medicine. It is the proposition that the future of integrative healthcare depends upon creating more scientifically rigorous, epistemically inclusive, ethically governed, culturally responsive, and equitable relationships among knowledge, nature, medicine, and healthcare systems.

Limitations of the Study

This study has several limitations. As an integrative literature review and conceptual analysis, it synthesizes interdisciplinary evidence rather than establishing the clinical efficacy of specific medicinal plants or therapies. Differences in methods and evidentiary standards across biblical scholarship, traditional and Indigenous medicine, pharmaceutical science, public health, and integrative healthcare also limit direct comparison across disciplines.

The emphasis on English-language and accessible published sources may underrepresent medicinal knowledge preserved through local languages, oral traditions, and community practices, particularly in African and Indigenous contexts. In addition, substantial variation in medicinal plants, preparations, practices, and regulatory environments limits generalization across herbal and traditional medicine.

The analysis of phamaceutical influence examines structural influences such as commercialization, intellectual property, research investment, regulation, and institutional authority but does not portray the pharmaceutical sector as monolithic. Similarly, Revelation 22:2 serves as a conceptual point of departure rather than a comprehensive exegetical claim; the study does not prescribe an exclusively physical, medicinal, spiritual, symbolic, or eschatological interpretation of "the healing of the nations."

Future research should examine specific medicinal plants and practices, compare regulatory and integration approaches across settings, investigate community perspectives on commercialization and benefit sharing, and evaluate clinical and population-health outcomes of evidence-informed integrative healthcare.

Implications of the Study

The findings have implications for healthcare practice, traditional and Indigenous knowledge, pharmaceutical research and development, and the broader integration of plant-based therapies into contemporary healthcare. Collectively, they suggest that medicinal plants, traditional knowledge, and pharmaceutical science need not be treated as competing domains. Their productive relationship depends on appropriate evidence, patient safety, cultural recognition, ethical development, and responsible use.

For healthcare practice, herbal and traditional-medicine use should be recognized as part of the clinical context, particularly because patients may use these therapies alongside prescription medications. Respectful communication and routine inquiry about herbal use can help healthcare professionals identify potential interactions, contraindications, product-quality concerns, and other safety issues. Such communication can also support more informed and coordinated decision-making between patients and healthcare providers.

Traditional and Indigenous medicinal knowledge remains an important source of therapeutic insight and should be recognized without assuming that historical use alone establishes clinical efficacy. Documentation and scientific investigation can help identify promising medicinal practices while preserving the cultural and historical contexts from which they originate. Collaboration with knowledge-holding communities is particularly important when medicinal knowledge is transmitted orally or maintained collectively. When this knowledge contributes to research or commercial products, appropriate recognition, community participation, intellectual property considerations, and equitable benefit sharing should accompany its development.

Medicinal plants also remain important resources for pharmaceutical research and drug discovery. Systematic investigation through phytochemical characterization, pharmacological and toxicological testing, standardization, dosage determination, clinical evaluation, and quality assurance can help determine which traditional therapies or plant compounds have potential for further development. Research should distinguish traditional use and preliminary biological activity from demonstrated clinical efficacy and safety, particularly when products are intended to prevent or treat serious diseases. Promising findings should therefore provide a basis for further investigation rather than premature conclusions about therapeutic effectiveness.

Pharmaceutical development should also consider the origins of the knowledge and biological resources that contribute to innovation. Where traditional or Indigenous knowledge informs drug discovery or product development, transparency concerning attribution, intellectual property, commercialization, biodiversity conservation, and benefit sharing becomes important. Such considerations can support pharmaceutical innovation while ensuring that the communities and knowledge systems contributing to therapeutic discovery are appropriately recognized.

The biblical imagery of the leaves "for the healing of the nations" in Revelation 22:2 provides a broader context for considering these relationships. Without limiting the passage to a single medicinal, spiritual, symbolic, or eschatological interpretation, its association of leaves, healing, and nations invites reflection on the continuing place of plant resources in human well-being. In the context of this study, the imagery also raises broader questions about how societies recognize, investigate, protect, develop, and share medicinal knowledge and resources.

The implications therefore extend beyond a choice between medicinal herbs and pharmaceutical products. The more constructive direction is to strengthen the relationship among traditional knowledge, scientific investigation, pharmaceutical development, and healthcare practice. Such an approach can preserve valuable sources of medicinal knowledge while ensuring that therapeutic applications are evaluated for efficacy, safety, and quality and developed in ways that respect the people, communities, and natural resources from which that knowledge may originate.

VI. CONCLUSION

Medicinal plants have contributed to human healing across cultures and continue to influence pharmaceutical research, drug discovery, and contemporary healthcare. The evidence reviewed in this paper demonstrates that traditional and Indigenous knowledge, scientific investigation, pharmaceutical development, and integrative healthcare need not be viewed as competing approaches. Each contributes differently to understanding the therapeutic potential, safety, and appropriate use of medicinal plants.

The biblical imagery of the leaves being "for the healing of the nations" (Revelation 22:2, New International Version, 2011) provides a meaningful lens through which to consider the enduring relationship between plants and human health. Within contemporary healthcare, however, recognition of this relationship requires careful attention to evidence. Traditional use can identify promising therapeutic knowledge, while phytochemical, pharmacological, toxicological, and clinical research can determine how such knowledge may be translated into safe and effective applications. The strength of therapeutic claims should therefore remain consistent with the quality and relevance of the supporting evidence.

The future of medicinal plants in healthcare depends not on choosing between herbal and pharmaceutical medicine, but on strengthening the processes through which therapeutic knowledge is investigated, developed, and responsibly applied. Pharmaceutical research and development can play an important role by investigating promising plant-based therapies while maintaining rigorous standards for efficacy, safety, quality, and clinical use. At the same time, responsible development should recognize the traditional and Indigenous knowledge that may contribute to discovery and address intellectual property, biodiversity, and equitable benefit sharing.

Ultimately, medicinal plants represent both an enduring source of therapeutic knowledge and an important area for continued scientific inquiry. A balanced approach that respects their historical and cultural foundations while subjecting therapeutic claims to appropriate scientific evaluation offers a credible pathway for advancing pharmaceutical innovation and evidence-informed integrative healthcare.

REFERENCES

[1] Alum, E. U. (2024). The role of indigenous knowledge in advancing the therapeutic use of medicinal plants: Challenges and opportunities. *Plant Signaling & Behavior, 19*(1), 2439255. https://doi.org/10.1080/15592324.2024.2439255

[2] Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. *Nature Reviews Drug Discovery, 20*, 200–216. https://doi.org/10.1038/s41573-020-00114-z

[3] Berlowitz, I., Pesantes, M. A., Cárdenas Palacios, C., Martin-Soelch, C., Wolf, U., & Maake, C. (2025). Towards culturally inclusive healthcare in Peru: Mapping epistemic concepts in contemporary Indigenous Amazonian medicine—Traditional healers' perspectives. *PLOS Global Public Health, 5*(1), e0003912. https://doi.org/10.1371/journal.pgph.0003912

[4] Cheng, W., Xia, K., Wu, S., & Li, Y. (2023). Herb-drug interactions and their impact on pharmacokinetics: An update. *Current Drug Metabolism, 24*(1), 28–69. https://doi.org/10.2174/1389200224662030116113240

[5] Cornelius, S. F., & Van Wyk, B.-E. (2024). An updated inventory of medicinal and ritual plants of southern Africa. *Journal of Ethnopharmacology, 332*, 118361. https://doi.org/10.1016/j.jep.2024.118361

[6] Indrayanto, G. (2024). Regulation and standardization of herbal drugs: Current status, limitations, challenges and future prospects. *Profiles of Drug Substances, Excipients and Related Methodology, 49*, 153–199. https://doi.org/10.1016/bs.podrm.2023.11.003

[7] Jütte, R., Heinrich, M., Helmstädter, A., Langhorst, J., Meng, G., Niebling, W., Pommerening, T., & Trampisch, H. J. (2024). A review of the WHO strategy on traditional, complementary, and integrative medicine from the perspective of academic consortia for integrative medicine and health. *Frontiers in Medicine, 11*, 1395698. https://doi.org/10.3389/fmed.2024.1395698

[8] Kongkaew, C., Phan, D. T. A., Janusorn, P., & Mongkhon, P. (2024). Estimating adverse events associated with herbal medicines using pharmacovigilance databases: Systematic review and meta-analysis. *JMIR Public Health and Surveillance, 10*, e63808. https://doi.org/10.2196/63808

[9] Mathewson, D. L. (2021). The destiny of the nations in Revelation 21:1–22:5: A reconsideration. *Tyndale Bulletin*.

[10] Meverden, A. E. (2026). The metonymic power of healing leaves: Reading Revelation 22:2 with the Caryatid Relief. *Interpretation: A Journal of Bible and Theology, 80*(1), 33–46. https://doi.org/10.1177/00209643251379042

[11] New International Version Bible. (2011). Zondervan. (Original work published 1978).

[12] Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ, 372*, n71. https://doi.org/10.1136/bmj.n71

[13] Raclariu-Manolică, A. C., Mauvisseau, Q., & de Boer, H. J. (2023). Horizon scan of DNA-based methods for quality control and monitoring of herbal preparations. *Frontiers in Pharmacology, 14*, 1179099. https://doi.org/10.3389/fphar.2023.1179099

[14] Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. *Journal of Business Research, 104*, 333–339. https://doi.org/10.1016/j.jbusres.2019.07.039

[15] U.S. Food and Drug Administration. (2026). *Botanical drug products*. U.S. Department of Health and Human Services.

[16] Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C. (2023). Advancing herbal medicine: Enhancing product quality and safety through robust quality control practices. *Frontiers in Pharmacology, 14*, 1265178. https://doi.org/10.3389/fphar.2023.1265178

[17] Whittemore, R., & Knafl, K. (2005). The integrative review: Updated methodology. *Journal of Advanced Nursing, 52*(5), 546–553. https://doi.org/10.1111/j.1365-2648.2005.03201.x

[18] Williams, S. J., Martin, P., & Gabe, J. (2011). The pharmaceuticalisation of society? A framework for analysis. *Sociology of Health & Illness, 33*(5), 710–725. https://doi.org/10.1111/j.1467-9566.2011.01320.x

[19] World Health Organization. (2025a). *Global traditional medicine strategy 2025–2034*. World Health Organization.

[20] World Health Organization. (2025b). *WHO global report on traditional, complementary and integrative medicine 2024*. World Health Organization.

[21] World Health Organization. (2025c). *Integration of traditional, complementary and integrative medicine into health systems: Conceptual framework*. World Health Organization.

[22] World Health Organization. (2025). *Traditional medicine*. World Health Organization.

[23] World Health Organization. (2026a). *Traditional medicine biodiversity and Indigenous knowledges*. WHO Global Traditional Medicine Centre.

[24] World Health Organization. (2026b, June 23). *WHO advances global harmonization of herbal medicine standards through expert meeting on the development of international herbal pharmacopoeia*.

[25] World Intellectual Property Organization. (2024). *WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge*. WIPO.

[26] D'Almeida SA, Gbomor SE, Osaio-Kamara B, Olagunju MT, Abodunrin OR, Foláyan MO (2024) A scoping review of the use of traditional medicine for the management of ailments in West Africa. PLoS ONE 19(7): e0306594. https://doi.org/10.1371/journal.pone.03065942024

[27] Davis, C., & Choisy, P. (2024). Medicinal plants meet modern biodiversity science Current Biology, 34, R158-R173. https://doi.org/10.1016/j.cub.2023.12.038

[28] Nasim, N., Sandeep, I. S., & Mohanty, S. (2022). Plant-derived natural products for drug discovery: Current approaches and prospects. *The Nucleus, 65*, 399–411.